Citing "market conditions," the company, which last month released three new biomarker panels and plans to release a fourth in the next several weeks, pulled the initial public offering it filed for last December.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.